Skip to content
Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
ABOUT US
ABOUT US
CAREERS
CONTACT US
PIPELINE
INHBE siRNA
IL-13 x TSLP
TMPRSS6
MYOSTATIN (GDF8)
α4β7 x IL-23
IL‑31 x IL‑4Rα
UPDATES
PARTNERSHIP
LICENSING
Press Releases
Updates
Search
Search
All Resources
Press Releases
Videos
All Resources
Press Releases
Videos
Press Releases
The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy
Read Article
Press Releases
Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
Read Article
Press Releases
The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy
Read Article
Press Releases
Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
Read Article
Clear search querie
